Search

You searched for "transurethral"

199 results found

Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial?

12 October 2022 | | Urologic Oncology | #BladderCancer, #blcsm, cytosine arabinoside, intravesical therapy, mitomycin C, non-muscle-invasive bladder cancer, randomised trial, #uroonc, urinary pH
Mitomycin C (MMC) is often used as an intravesical therapy for low / intermediate risk non-muscle invasive bladder cancer. This randomised controlled trial (RCT) was designed to assess the safety and efficacy of MMC + cytosine arabinoside (Ara-C). Ara-C was...

Outcomes of sarcomatoid differentiation in urothelial carcinoma

5 December 2022 | | Urologic Oncology | #BladderCancer, #scmsm, #uroonc, bladder cancer, neoadjuvant therapy, pathological outcomes, sarcomatoid differentiation, survival, urothelial carcinoma
Sarcomatoid differentiation is a rare variant of urothelial carcinoma (UC) seen in 0.6% of cases. Its response to neo-adjuvant chemotherapy (NAC) has not been well reported. The authors have done a retrospective analysis of patients undergoing cystectomy between 1995 and...

Evaluation of the learning curve for learning MRI-US fusion prostate biopsies

7 July 2020 |
With the advent of one-stop prostate cancer diagnostic clinics, the findings of this study are of interest to readers who may be implementing MRI-US transrectal or transperineal fusion biopsies to their clinical practice. This prospective cohort study evaluated 779 consecutive...

Visual-estimation (cognitive), image-fusion (software) and in-bore targeted prostate biopsy: is there an optimal approach?

3 March 2021 | | Urologic Oncology, Technological Developments
The diagnostic superiority of multiparametric magnetic resonance imaging (mpMRI) prior to targeted and systematic prostate biopsy over systematic transrectal ultrasound-guided (TRUS) biopsy alone in the detection of clinically significant prostate cancer (csPCa) has been proven by multiple level 1 studies...

Erectile dysfunction part II: treatment

1 May 2014 | | Andrology
Introduction The identification of specific risk factors associated with erectile dysfunction (ED) allows patients with mild or moderate ED to undergo a series of lifestyle changes, which may provide enough improvement in the erectile function to avoid pharmacotherapies. Cessation of...

Bladder cancer: where are we with intravesical therapies?

1 July 2016 | | Urologic Oncology
In the United Kingdom, almost 10,500 new cases of bladder cancer were identified in 2013, with over 5000 deaths in 2012 [1]. Seventy percent of new cases will be non-muscle invasive bladder cancer (NMIBC) at diagnosis and therefore will be...

Long-term oncologic outcomes of salvage cryoablation for rrPC

1 July 2017 | | Urologic Oncology
Of patients undergoing radiotherapy (RT) for prostate cancer (PC), at least 15-20% will experience recurrence. Although salvage prostatectomy achieves durable oncological outcomes at 10 years, it is associated with significantly high morbidity. Thus, the majority of men with radio-recurrent prostate...

Demanding cases or nightmares in uro-oncology? Jan/Feb 2023

6 January 2023 | | Urologic Oncology
Radical surgical treatment of prostate cancer has become minimally invasive owing to robotic assisted laparoscopic technology [1]. Patients who undergo robotic assisted radical prostatectomy (RARP) often have lower risk of morbidity compared to an open approach. However, patients with a...

An old resectoscope in a wooden case

1 January 2017 | | Technological Developments
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). In the last article I said I would write about a particular artefact...

A review of the diagnosis and management of urethral caruncles

1 November 2017 | | Functional Urology
Introduction The innocuous urethral caruncle is the most common benign urethral lesion in females. It can pose a significant challenge to urologists due to the plethora of differentials and poor evidence surrounding management. In 1926, Ferrier eloquently described the macroscopic...

Focal therapies in prostate cancer

1 November 2018 | | Technological Developments, Urologic Oncology
The standard of care in the management of prostate cancer has, to date, always been to treat the whole gland. This has ranged from surveillance, surgical excision / prostatectomy or external beam radiotherapy / whole gland brachytherapy. With the evolution...

Complications of CISC

1 July 2014 | | Infection, Functional Urology, Neurourology
Introduction Clean intermittent self catheterisation (CISC) was first introduced and popularised by Lapides in 1972. Since then its utilisation has become widespread and it is now commonly used throughout the world as the preferred means of facilitating complete and effective...